Finance

Lists
EBS:NYSE
Emergent Biosolutions Inc
6,91 $
0,00%
(0,00) 1D
6,80 $
-1,59% (-0,11)
After hours
Closed: 14 қаз., 16:00:03 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for EBS...
Open
6,87 $
High
7,07 $
Low
6,81 $
Mkt. cap
354,30 млн
Avg. vol.
1,14 млн
Volume
762,10 м.
52-wk high
14,06 $
52-wk low
4,36 $
EPS
-3,51 $
Beta
2,28
Shares outstanding
51,27 млн
No. of employees
900
Open
6,87 $
High
7,07 $
Low
6,81 $
Mkt. cap
354,30 млн
Avg. vol.
1,14 млн
Volume
762,10 м.
52-wk high
14,06 $
52-wk low
4,36 $
EPS
-3,51 $
Beta
2,28
Shares outstanding
51,27 млн
No. of employees
900
News stories
From web sources and news partners
Profile
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes. Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid. During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded. Wikipedia
About Emergent Biosolutions Inc
CEORobert G. Kramer Sr. | Joseph C. Papa
Employees900
Founded1998 ж. 05 қыр.
HeadquartersРоквилл, Мэриленд, Америка Құрама Штаттары
Sector-
Analyst ratings
Based on 2 analysts giving stock ratings to EBS in the past 3 months
Hold
Buy
1
Hold
0
Sell
1
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for EBS in the last 3 months.
Highest
Current 6,91 $
10,00 $ (+44,72%)
Average
10,00 $ (+44,72%)
Lowest
10,00 $ (+44,72%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
10,00 $
+44,7%
09/09/2026
Jessica Fye
J.P. Morgan
Sell
Initiated
-
-
08/21/2026
Next call 14 күннен кейін
28 қаз., ср, 23:00
Fiscal period
Q3 2026
- / -0,39 $
Revenue / Est. (USD)
- / 123,20 млн
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
231,10 млн
148,70 млн
156,10 млн
234,30 млн
Cost of goods sold
99,00 млн
94,00 млн
82,40 млн
106,10 млн
Cost of revenue
99,00 млн
94,00 млн
82,40 млн
106,10 млн
Research and development expenses
200,00 м.
-600,00 м.
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
28,30 млн
61,60 млн
46,60 млн
44,60 млн
Operating expense
44,80 млн
77,30 млн
63,10 млн
61,80 млн
Total operating expenses
143,80 млн
171,30 млн
145,50 млн
167,90 млн
Operating income
87,30 млн
-22,60 млн
10,60 млн
66,40 млн
Other non operating income
-3,70 млн
-8,10 млн
13,90 млн
-
EBT including unusual items
57,60 млн
-50,70 млн
13,40 млн
-166,30 млн
EBT excluding unusual items
68,40 млн
-45,40 млн
13,50 млн
56,40 млн
Income tax expense
6,40 млн
3,90 млн
6,60 млн
13,90 млн
Effective tax rate
11,11%
-7,69%
49,25%
-8,36%
Other operating expenses
-
-
-
-
Net income
51,20 млн
-54,60 млн
6,80 млн
-180,20 млн
Net profit margin
22,15%
-36,72%
4,36%
-76,91%
Earnings per share
1,06
-0,43
0,21
0,60
Interest and investment income
-
-
-
-
Interest expense
-15,20 млн
-14,70 млн
-11,00 млн
-10,00 млн
Net interest expenses
-15,20 млн
-14,70 млн
-11,00 млн
-10,00 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
110,30 млн
2,40 млн
33,50 млн
89,90 млн
Gain or loss from assets sale
2,20 млн
-11,20 млн
800,00 м.
11,90 млн
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google қолданбалары